Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass.

Alcock R, Cottingham MG, Rollier CS, Furze J, De Costa SD, Hanlon M, Spencer AJ, Honeycutt JD, Wyllie DH, Gilbert SC, Bregu M, Hill AV.

Sci Transl Med. 2010 Feb 17;2(19):19ra12. doi: 10.1126/scitranslmed.3000490.

2.

Viral vectors in malaria vaccine development.

Limbach KJ, Richie TL.

Parasite Immunol. 2009 Sep;31(9):501-19. doi: 10.1111/j.1365-3024.2009.01141.x. Review.

3.

Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice.

Pearson FE, McNeilly CL, Crichton ML, Primiero CA, Yukiko SR, Fernando GJ, Chen X, Gilbert SC, Hill AV, Kendall MA.

PLoS One. 2013 Jul 9;8(7):e67888. doi: 10.1371/journal.pone.0067888. Print 2013.

4.

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.

Sutter G, Staib C.

Curr Drug Targets Infect Disord. 2003 Sep;3(3):263-71. Review.

PMID:
14529359
5.

Adenoviruses as vaccine vectors.

Tatsis N, Ertl HC.

Mol Ther. 2004 Oct;10(4):616-29. Review.

6.

Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines.

Xing Z, Santosuosso M, McCormick S, Yang TC, Millar J, Hitt M, Wan Y, Bramson J, Vordermeier HM.

Curr Gene Ther. 2005 Oct;5(5):485-92. Review.

PMID:
16250889
7.

Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.

Pinto AR, Fitzgerald JC, Giles-Davis W, Gao GP, Wilson JM, Ertl HC.

J Immunol. 2003 Dec 15;171(12):6774-9.

8.

Overcoming immunity to a viral vaccine by DNA priming before vector boosting.

Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ.

J Virol. 2003 Jan;77(1):799-803.

9.
10.

Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.

Juillard V, Villefroy P, Godfrin D, Pavirani A, Venet A, Guillet JG.

Eur J Immunol. 1995 Dec;25(12):3467-73.

PMID:
8566039
11.

Gene therapy and viral vaccination: the interface.

Wilkinson GW, Borysiewicz LK.

Br Med Bull. 1995 Jan;51(1):205-16. Review.

PMID:
7767644
12.

MVA as a vector for vaccines against HIV-1.

Im EJ, Hanke T.

Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S89-97. Review.

PMID:
15285708
13.

Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells.

Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, Sieuwerts M, Weichold F, Damen I, Kaspers J, Lemckert A, van Meerendonk M, van der Vlugt R, Holterman L, Hone D, Skeiky Y, Mintardjo R, Gillissen G, Barouch D, Sadoff J, Goudsmit J.

J Gen Virol. 2006 Aug;87(Pt 8):2135-43.

PMID:
16847108
14.

Use of adenovirus as a model system to illustrate a simple method using standard equipment and inexpensive excipients to remove live virus dependence on the cold-chain.

Stewart M, Ward SJ, Drew J.

Vaccine. 2014 May 19;32(24):2931-8. doi: 10.1016/j.vaccine.2014.02.033. Epub 2014 Mar 21.

PMID:
24662703
15.

Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle.

Dulal P, Wright D, Ashfield R, Hill AV, Charleston B, Warimwe GM.

Vaccine. 2016 Apr 29;34(20):2296-8. doi: 10.1016/j.vaccine.2016.03.061. Epub 2016 Mar 25.

16.

New approaches to the development of virus vaccines for veterinary use.

Yamanouchi K, Barrett T, Kai C.

Rev Sci Tech. 1998 Dec;17(3):641-53. Review.

PMID:
9850535
17.

High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector.

Vogels R, Zuijdgeest D, van Meerendonk M, Companjen A, Gillissen G, Sijtsma J, Melis I, Holterman L, Radosevic K, Goudsmit J, Havenga MJ.

J Gen Virol. 2007 Nov;88(Pt 11):2915-24.

PMID:
17947512
18.

Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes.

Dai K, Liu Y, Liu M, Xu J, Huang W, Huang X, Liu L, Wan Y, Hao Y, Shao Y.

Vaccine. 2008 Sep 15;26(39):5062-71. doi: 10.1016/j.vaccine.2008.06.011. Epub 2008 Jun 23.

PMID:
18573290
19.

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA.

Nature. 2002 Jan 17;415(6869):331-5.

PMID:
11797011
20.

Poxvirus-based vectors as vaccine candidates.

Tartaglia J, Pincus S, Paoletti E.

Crit Rev Immunol. 1990;10(1):13-30. Review.

PMID:
2407263

Supplemental Content

Support Center